NCT06513533View on ClinicalTrials.gov

Dimethyl Fumarate in Adrenomyeloneuropathy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2028

Conditions
Adrenomyeloneuropathy Without Cerebral Involvement
Interventions
OTHER

Placebo

1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily

DRUG

Dimethyl fumarate

1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily

Trial Locations (3)

20014

NOT_YET_RECRUITING

Donostia University Hospital, Donostia / San Sebastian

28041

RECRUITING

University Hospital 12 de Octubre, Madrid

08907

RECRUITING

Bellvitge University Hospital, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

collaborator

Spanish Clinical Research Network - SCReN

NETWORK

collaborator

Institut d'Investigació Biomèdica de Bellvitge

OTHER

lead

Pujol, Aurora, M.D.

INDIV